Navigation Links
China-Biotics, Inc. Comments on Market Rumors
Date:9/10/2010

China-Biotics, Inc. Comments on Market Rumors -- SHANGHAI, Sept. 10 /PRNewswire-Asia-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Chemical Click to view news release full screen  

China-Biotics, Inc. Comments on Market Rumors

 

SHANGHAI, Sept. 10 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics" or "the Company"), a leading developer, manufacturer and distributor of probiotics products in China, today confirms that there has been an organized effort to distribute false rumors regarding the Company by emails, phone calls and websites. The Company suspects this is motivated by short selling interest in the Company's stock. These messages are false and damage China-Biotics' corporate image and its management's credibility. The Company has acted in a legal and ethical manner and it has not provided false disclosures of the Company's operations or financial data to investors or the United States securities authorities. China-Biotics is working with its legal counsel and the relevant authorities on further action against those responsible.

About China-Biotics

China-Biotics, Inc. ("China-Biotics," the "Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements in China. Through its wholly owned subsidiaries, Shanghai Shining Biotechnology Co., Ltd. and Growing Bioengineering (Shanghai) Co. Ltd., the Company develops and produces its proprietary product portfolio. Currently, the retail products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang province. The company currently sells bulk products to institutional customers such as dairy and animal feed producers, as well as pharmaceutical companies. In February 2010, China-Biotics began its commercial production in China's largest probiotics production facility to meet growing demand in China. For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement

The information in this release contains forward-looking statements which involve risks and uncertainties, including statements regarding the Company's capital needs, business strategy and expectations. Any statements contained herein that are not statements of historical fact may be deemed to be forward- looking statements, which may be identified by terminology such as "may," "should," "will," "expect," "plan," "intend," "anticipate," "believe," "estimate," "predict," "potential," "forecast," "project," or "continue," the negative of such terms or other comparable terminology. Readers should not rely on forward-looking statements as predictions of future events or results. Any or all of the Company's forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions, risks and uncertainties and other factors which could cause actual events or results to be materially different from those expressed or implied in the forward-looking statements. In evaluating these statements, readers should consider various factors, including the risks described in "Item 1A. Risk Factors" beginning on page 17 and elsewhere in the Company's 2010 Annual Report on Form 10-K. These factors may cause the Company's actual results to differ materially from any forward- looking statement. In addition, new factors emerge from time to time and it is not possible for the Company to predict all factors that may cause actual results to differ materially from those contained in any forward-looking statements. The Company disclaims any obligation to publicly update any forward-looking statements to reflect events or circumstances after the date of this document, except as required by applicable law.

For more information, please contact: Travis Cai Chief Financial Officer China-Biotics, Inc. Email: traviscai@chn-biotics.com Shiwei Yin/Kevin Theiss Grayling Phone: +1-646-284-9474 Email: shiwei.yin@grayling.com kevin.theiss@grayling.com
'/>"/>

SOURCE China-Biotics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China-Biotics, Inc. Announces US$20 million Share Buyback Program
2. China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010
3. China-Biotics, Inc. Begins Trial Production at New Facility, Affirms 2010 Revenue Guidance
4. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
5. NeoStem Comments on Recent Court Ruling Blocking the Federal Governments Funding of Embryonic Stem Cell Research
6. Fort Worth Attorney Dwain Dent Comments on Final Judgment in Case That Left Hundreds of Babies Dead or Injured
7. Whistleblower Doctor Comments on His Case that Helped Expose Illegal Marketing of Topamax
8. AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma
9. Endologix Comments on Alleged Patent Infringement
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ACRO Comments on NEJM Article on Globalization of Clinical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... France , Germany , Italy ... ). It includes a 10-year epidemiology forecast for the total prevalent ... sex in these markets. GD epidemiology report is written and developed by ... and market-driven, providing expert analysis of disease trends in the 7MM. ... Italy , Spain , UK, and ...
(Date:2/4/2016)... 2016  The Senior Care Pharmacy Coalition (SCPC) ... Chairman Jason Chaffetz (R-UT) and Ranking ... hearing , "Developments in the Prescription Drug Market," ... questions about abusive pharmacy benefit manager (PBM) pricing ... Ranking Member Elijah Cummings (D-MD) are diligent, serious ...
(Date:2/4/2016)... , Feb. 4, 2016 Wegener ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline ... Wegener Polyangiitis,s therapeutic pipeline. This report provides ... Polyangiitis, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... The ... Popeyes Louisiana Kitchen restaurants, launched the 14th annual “Appetite for a Cure” campaign ... with muscular dystrophy, ALS and related diseases that severely limit strength and mobility. ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to once again host, Swirl, A Wine Tasting Event at the La Gorce ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Give ... allow users to search for and donate to Give To Cure’s campaign that is ... app that lets users make and share payments through a smart device. In 2015 ...
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS is ... to provide the most effective tattoo removal today, Dr. Bentkover is the only doctor ... by Cynosure, the PicoSure has been approved by the Food and Drug Administration (FDA) ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... practical mobile kitchens, recently announced the debut of their latest mobile kitchen model, ... Kitchens provides organizations with modern, high-volume commercial kitchens for use anywhere in the ...
Breaking Medicine News(10 mins):